Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net (loss) income	$ (15,305)	$ (33,867)	$ 5,285
Adjustments to reconcile net (loss) income to net cash flows provided by (used in) operating activities
Depreciation	1,846	740	693
Accretion of debt discount and loan costs	11,508	4,138	2,392
Amortization of intangible assets	6,981	5,157	5,425
Provision for (recovery from) inventory obsolescence	197	(56)	243
Impairment loss on equipment	0	78	0
Stock-based compensation expense	5,416	5,941	14,801
Deferred income taxes	0	40	(15,972)
Bargain purchase gain	0	0	(27,336)
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable	(25,163)	(4,640)	(5,884)
Inventories	(6,102)	741	2,448
Prepaid expenses and other assets	(581)	422	526
Accounts payable and accrued expenses	32,275	(2,807)	6,644
Deferred revenue	0	0	(21,716)
Net cash flows provided by (used in) operating activities	11,072	(24,113)	(32,451)
Investing activities:
Product acquisitions	(30,685)	(1,951)	(5,853)
Acquisitions of equipment	(79)	(112)	(11)
Net cash flows used in investing activities	(30,764)	(2,063)	(5,864)
Financing activities:
Proceeds from exercise of stock options	2,321	670	439
Proceeds from issuance of common stock, less underwriters discount	48,000	0	0
Proceeds from issuance of Series B preferred stock	0	50,000	0
Payment on note payable	(67,346)	0	(30,000)
Proceeds from notes payable	59,987	0	60,000
Equity finance costs	(410)	(1,417)	0
Payment of deferred financing fees	0	(450)	(2,948)
Loss on refinancing of former debt	(2,794)	0	0
Net cash flows provided by financing activities	39,758	48,803	27,491
Net change in cash and cash equivalents	20,066	22,627	(10,824)
Cash and cash equivalents at beginning of year	43,822	21,195	32,019
Cash and cash equivalents at end of year	63,888	43,822	21,195
Cash paid for interest	6,809	6,053	5,285
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings	$ 12,500	$ 12,500
Common stock issuance upon retirement, shares	2,119,925	2,119,925
Common stock issuance upon retirement	$ 5,300	$ 5,300
Accrued financing expenses		600
Fair value of bargain purchase price of BELBUCA acquisition		27,300	27,300
Fair value of warrants, in connection with CRG term loan		$ 6,000	$ 6,000
Series B Non-Voting Convertible Preferred Stock
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings	12,500
Accrued financing expenses	$ 600